[{"id":"db802908-d352-4788-a1a5-ab4e959f4c3b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03009240","created_at":"2024-03-12T22:20:15.146Z","updated_at":"2024-07-02T16:35:15.595Z","phase":"Phase 1","brief_title":"Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia","source_id_and_acronym":"NCT03009240","lead_sponsor":"City of Hope Medical Center","biomarkers":" MIR155 • NFKB1","pipe":" | ","alterations":" miR-155 expression • NFKB1 expression","tags":["MIR155 • NFKB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e miR-155 expression • NFKB1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e decitabine • pevonedistat (MLN4924)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/21/2017","start_date":" 08/21/2017","primary_txt":" Primary completion: 12/15/2024","primary_completion_date":" 12/15/2024","study_txt":" Completion: 12/15/2024","study_completion_date":" 12/15/2024","last_update_posted":"2024-03-08"},{"id":"efbf6108-cc54-4f0c-937b-4e1967104f96","acronym":"","url":"https://clinicaltrials.gov/study/NCT01895842","created_at":"2021-01-18T08:30:36.207Z","updated_at":"2024-07-02T16:35:27.732Z","phase":"Phase 1","brief_title":"Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)","source_id_and_acronym":"NCT01895842","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" JAK2 • NFKB1","pipe":" | ","alterations":" JAK2 mutation","tags":["JAK2 • NFKB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib)"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 02/01/2014","start_date":" 02/01/2014","primary_txt":" Primary completion: 04/02/2019","primary_completion_date":" 04/02/2019","study_txt":" Completion: 04/02/2019","study_completion_date":" 04/02/2019","last_update_posted":"2023-11-29"},{"id":"edd745a7-2dc4-41e1-bbdc-763b0a5fc963","acronym":"","url":"https://clinicaltrials.gov/study/NCT05172739","created_at":"2021-12-29T13:53:40.637Z","updated_at":"2024-07-02T16:36:19.050Z","phase":"Phase 4","brief_title":"Opioid Free Anaesthesia-Analgesia Strategy on Surgical Stress and Immunomodulation in Elective VATS-Lobectomy for NSCLC","source_id_and_acronym":"NCT05172739","lead_sponsor":"University of Crete","biomarkers":" IL6 • TNFA • HIF1A • CXCL8 • IL10 • NFKB1","pipe":" | ","alterations":" IL10 elevation","tags":["IL6 • TNFA • HIF1A • CXCL8 • IL10 • NFKB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL10 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ondansetron"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2021-12-29"},{"id":"4ad14ef8-b4e9-4380-9939-f8359daf8bbc","acronym":"HEAD-MET","url":"https://clinicaltrials.gov/study/NCT03510390","created_at":"2021-01-18T17:16:43.390Z","updated_at":"2024-07-02T16:36:20.573Z","phase":"","brief_title":"Metformin in Head and Neck Squamous Cell Carcinoma: Effect on Tissue Oxygenation","source_id_and_acronym":"NCT03510390 - HEAD-MET","lead_sponsor":"University Hospital Inselspital, Berne","biomarkers":" TP53 • VEGFA • HIF1A • HMOX1 • NFKB1 • CA9 • CASP3 • MMP9 • SERPINE1 • PER1 • APEX1 • EGLN1 • EGR1 • HNF1A • PLAU • NCOA1","pipe":"","alterations":" ","tags":["TP53 • VEGFA • HIF1A • HMOX1 • NFKB1 • CA9 • CASP3 • MMP9 • SERPINE1 • PER1 • APEX1 • EGLN1 • EGR1 • HNF1A • PLAU • NCOA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 06/13/2018","start_date":" 06/13/2018","primary_txt":" Primary completion: 09/15/2021","primary_completion_date":" 09/15/2021","study_txt":" Completion: 11/15/2021","study_completion_date":" 11/15/2021","last_update_posted":"2021-11-18"},{"id":"8284cc8c-721f-44a1-8e24-661469416818","acronym":"","url":"https://clinicaltrials.gov/study/NCT04403568","created_at":"2021-01-18T21:14:27.726Z","updated_at":"2024-07-02T16:36:24.407Z","phase":"Phase 1","brief_title":"Testing the Synergism of Phytonutrients, Curcumin and Ursolic Acid, to Target Molecular Pathways in the Prostate","source_id_and_acronym":"NCT04403568","lead_sponsor":"The University of Texas Health Science Center at San Antonio","biomarkers":" NFKB1","pipe":"","alterations":" ","tags":["NFKB1"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2021-09-15"},{"id":"5c900d9d-bc57-4f78-ab9b-fa447627f547","acronym":"","url":"https://clinicaltrials.gov/study/NCT04924686","created_at":"2021-06-14T18:52:33.088Z","updated_at":"2024-07-02T16:36:29.100Z","phase":"","brief_title":"Changes of Muramyl Dipeptide in Intestinal and Extra-intestinal Diseases","source_id_and_acronym":"NCT04924686","lead_sponsor":"Zhujiang Hospital","biomarkers":" NFKB1","pipe":"","alterations":" ","tags":["NFKB1"],"overall_status":"Recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 05/10/2020","start_date":" 05/10/2020","primary_txt":" Primary completion: 06/10/2023","primary_completion_date":" 06/10/2023","study_txt":" Completion: 08/15/2023","study_completion_date":" 08/15/2023","last_update_posted":"2021-06-14"},{"id":"e33b78ef-4ce9-42bb-a172-8518d3e97f23","acronym":"","url":"https://clinicaltrials.gov/study/NCT00381940","created_at":"2021-01-28T18:52:11.240Z","updated_at":"2024-07-02T16:36:32.862Z","phase":"Phase 2","brief_title":"Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy","source_id_and_acronym":"NCT00381940","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD34 • NFKB1","pipe":"","alterations":" ","tags":["CD34 • NFKB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • ifosfamide • vinorelbine tartrate • Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 01/01/2007","start_date":" 01/01/2007","primary_txt":" Primary completion: 06/01/2008","primary_completion_date":" 06/01/2008","study_txt":" Completion: 12/31/2016","study_completion_date":" 12/31/2016","last_update_posted":"2021-03-24"},{"id":"ebeeadce-a5b3-4e8b-a248-5925a2749718","acronym":"","url":"https://clinicaltrials.gov/study/NCT00389805","created_at":"2021-01-18T01:21:26.551Z","updated_at":"2024-07-02T16:37:05.692Z","phase":"Phase 1/2","brief_title":"Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors","source_id_and_acronym":"NCT00389805","lead_sponsor":"University of California, Davis","biomarkers":" BCL2 • BCL2L1 • NFKB1","pipe":" | ","alterations":" BCL2 expression • NFKB1 expression","tags":["BCL2 • BCL2L1 • NFKB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • NFKB1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 03/01/2005","start_date":" 03/01/2005","primary_txt":" Primary completion: 12/01/2006","primary_completion_date":" 12/01/2006","study_txt":" Completion: 06/01/2007","study_completion_date":" 06/01/2007","last_update_posted":"2018-10-31"},{"id":"1aec247f-d9c9-47b5-9ab1-6f77319a009e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01016730","created_at":"2021-01-18T03:59:13.786Z","updated_at":"2024-07-02T16:37:13.784Z","phase":"Phase 1","brief_title":"Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma","source_id_and_acronym":"NCT01016730","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NFKB1","pipe":"","alterations":" ","tags":["NFKB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 01/22/2010","start_date":" 01/22/2010","primary_txt":" Primary completion: 01/07/2015","primary_completion_date":" 01/07/2015","study_txt":" Completion: 01/07/2015","study_completion_date":" 01/07/2015","last_update_posted":"2018-02-20"},{"id":"f77dd0f2-224d-4369-b113-269fa95df791","acronym":"COMBOSTAT","url":"https://clinicaltrials.gov/study/NCT00837174","created_at":"2021-01-18T03:11:14.498Z","updated_at":"2024-07-02T16:37:17.747Z","phase":"Phase 2","brief_title":"Relapsed and/or Refractory Non-Hodgkin Lymphoma Study","source_id_and_acronym":"NCT00837174 - COMBOSTAT","lead_sponsor":"The Methodist Hospital Research Institute","biomarkers":" CCND1 • NFKB1","pipe":"","alterations":" ","tags":["CCND1 • NFKB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • Zolinza (vorinostat)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/01/2010","start_date":" 06/01/2010","primary_txt":" Primary completion: 05/01/2012","primary_completion_date":" 05/01/2012","study_txt":" Completion: 05/01/2012","study_completion_date":" 05/01/2012","last_update_posted":"2017-09-19"}]